ClinicalTrials.gg
CompletedNCT06579144Updated Jun 25, 2026

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

A Phase 1 interventional study of Efanesoctocog alfa in Hemophilia A, sponsored by Swedish Orphan Biovitrum. Completed at 7 sites in 4 countries. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Swedish Orphan Biovitrum · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing efanesoctocog alfa in Hemophilia A — 1 open to participants now, 5 under way, 2 of them phase 3. efanesoctocog alfa · Hemophilia A.

Enrollment
9th of 11
24 · median 74
Started
2025
with 3 others
Phase 1
2 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
5 of 11
Swedish Orphan Biovitrum

Among the 11 studies testing efanesoctocog alfa in Hemophilia A, this one is the 9th largest by enrollment, is one of 4 that started in 2025, is one of 2 in phase 1, and was the 7th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 11 studies testing efanesoctocog alfa in Hemophilia A is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About efanesoctocog alfa

efanesoctocog alfa: first FDA approval 2023 (ALTUVIIIO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing efanesoctocog alfa in Hemophilia A, or all of them as a file.
02

Study summary

Sobi.BIVV001-003 is an open-label, 2-period, fixed sequence study for intra-participant comparison of the PK profiles of efanesoctocog alfa and the extended half-life rFVIII products damactocog alfa pegol or turoctocog alfa pegol after a single i.v. injection in previously treated males, 18-65 years of age, with severe haemophilia A.

Participants who are receiving treatment with damoctocog alfa pegol (n\~12) or turoctocog alfa pegol (n\~12) will be enrolled in the study. The study will start with a screening period (up to 28 days), including a wash-out period prior to start of the actual study period.

During the the first visit, a single dose of damactocog alfa pegol or turoctocog alfa pegol (corresponding to the participant's pre-study treatment) will be administered. A PK sampling period will follow over 7 visits. Following completion of the PK sampling of the original treatment regimen, the patients will be given a single dose of efanesoctocog alfa at visit 8, after which a new PK sampling period will follow (visit 8-15).

The primary objective for the study is to compare the half-life of efanesoctocog alfa with that of the two comparator drugs after a single iv. injections.

Secondary objectives include comparison of area under the curve for efanesoctocog alfa vs. the two comparator drugs, characterization of PK parameters for all three drugs as well as well as to evaluate safety and tolerability of a single iv. injection of efanesoctocog alfa.

03

Conditions studied

  • Hemophilia A

Keywords

  • Haemophilia A
  • Blood coagulation disorder
  • efanesoctocog alfa
  • FVIII
  • Coagulation protein disorder
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be male, 18 to 65 years of age, inclusive, at the time of signing the form (ICF).
  • Severe haemophilia A, defined as \<1 IU/dL (\<1%) endogenous FVIII activity, as documented in historical medical records from a clinical laboratory demonstrating \<1% FVIII coagulant activity or a documented genotype known to produce severe haemophilia A.
  • Previous treatment for haemophilia A with any marketed recombinant and/or plasma derived FVIII for at least 150 exposure days.
  • Currently receiving treatment with damoctocog alfa pegol or turoctocog alfa pegol at Screening.

Exclusion criteria

Exclusion Criteria:

  • Any history of a positive inhibitor test, defined as >0.6 Bethesda units (BU)/mL in at least two consecutive Bethesda inhibitor assays, or any value greater than or equal to the lower sensitivity cut-off for laboratories with cut-offs for inhibitor detection between 0.7 and 1.0 BU/mL. Family history of inhibitors will not exclude the participant.
  • Positive FVIII inhibitor result (assessed by central laboratory), defined as ≥0.6 BU/mL at Screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Damactocog alfa pegol

    Patients treated with damactocog alfa pegol at the time of screening will receive one single injection with 50 IU/kg at visit 1, then one single dose 50 IU/kg with efanesoctocog alfa at visit 8.

    Drug: Efanesoctocog alfa

  • Active comparator
    Turoctocog alfa pegol

    Patients treated with turoctocog alfa pegol at the time of screening will receive one single injection with 50 IU/kg at visit 1, then one single dose 50 IU/kg with efanesoctocog alfa at visit 8.

    Drug: Efanesoctocog alfa

Interventions

  • Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)

    Also known as: BIVV001, Altuvoct, Altuviiio

06

What researchers measure

Primary outcomes

  1. Half-life (t½) of efanesoctocog alfa, damactocog alfa pegol and turoctocog alfa pegol after a single i.v. injection

    PK assessments will be based on FVIII activity levels determined by one-stage clotting assay

    Time frame: up to 7 days and 14 days after the administration of the respective drugs.

Secondary outcomes

  1. To compare the area under the curve zero to infinity (AUC∞) of efanesoctocog alfa with that of damoctocog alfa pegol and with that of turoctocog alfa pegol after a single i.v. injection.

    The area under the curve will be calculated based on drug concentration analyses from time zero to last quantifiable sample collection timepoint

    Time frame: up to 7 days and 14 days after the administration of the respective drugs.

  2. To characterize Cmax of efanesoctocog alfa and damoctocog alfa pegol or turoctocog alfa pegol after a single IV injection.

    Maximum concentration observed (Cmax) assessed by FVIII activity measurement by one-stage aPTT clotting assay

    Time frame: up to 7 days and 14 days after the administration of the respective drugs.

  3. To characterize clearance of efanesoctocog alfa and damoctocog alfa pegol or turoctocog alfa pegol after a single IV injection.

    Clearance of drug/s (CL) assessed by FVIII activity measurement by one-stage aPTT clotting assay

    Time frame: up to 7 days and 14 days after the administration of the respective drugs.

  4. To characterize volume of distribution of efanesoctocog alfa and damoctocog alfa pegol or turoctocog alfa pegol after a single IV injection.

    Volume of distribution (Vd) assessed by FVIII activity measurement by one-stage aPTT clotting assay

    Time frame: up to 7 days and 14 days after the administration of the respective drugs.

  5. To characterize mean residence time of efanesoctocog alfa and damoctocog alfa pegol or turoctocog alfa pegol after a single IV injection.

    Mean residence time (MRT) assessed by FVIII activity measurement by one-stage aPTT clotting assay

    Time frame: up to 7 days and 14 days after the administration of the respective drugs.

  6. To characterize incremental recovery of efanesoctocog alfa and damoctocog alfa pegol or turoctocog alfa pegol after a single IV injection.

    Incremental Recovery (IR) assessed by FVIII activity measurement by one-stage aPTT clotting assay

    Time frame: up to 7 days and 14 days after the administration of the respective drugs.

  7. To characterize time to specific plasma FVIII levels of efanesoctocog alfa and damoctocog alfa pegol or turoctocog alfa pegol after a single IV injection.

    Time to specific plasma FVIII:C levels (40%, 20%, and 10%) assessed by FVIII activity measurement by one-stage aPTT clotting assay

    Time frame: up to 7 days and 14 days after the administration of the respective drugs.

  8. To characterize time spent in plasma FVIII:C normal range for efanesoctocog alfa and damoctocog alfa pegol or turoctocog alfa pegol after a single IV injection.

    Time to spent in plasma FVIII:C normal range (50% - 150%) assessed by FVIII activity measurement by one-stage aPTT clotting assay

    Time frame: up to 7 days and 14 days after the administration of the respective drugs.

  9. To evaluate the safety and tolerability of a single IV injection of efanesoctocog alfa.

    All safety data from visit 1 up until the dose of efanesoctocog alfa for the first treatment period and then subsequently all safety data from the dose of efanesoctocog alfa until EoS will be analyzed for this outcome measure.

    Time frame: From first dose of comparator to end of study, approximately 1 month.

07

Study locations

7 sites
  • Sobi Investigational Site
    Sofia, Bulgaria
  • Sobi Investigational Site
    Bonn, Germany
  • Sobi Investigational site
    Frankfurt, Germany
  • Sobi Investigational Site
    Milan, Italy
  • Sobi Investigational Site
    A Coruña, Spain
  • Sobi Investigational Site
    Valencia, Spain
  • Sobi Investigational Site
    Zaragoza, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sobi's data sharing criteria and process for requesting access can be found at: https://www.sobi.com/en/policies

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Within 1 year following completion of the trial, or at the time of CSR finalization.

Access criteria: A decision on sharing will be based on the following: The scientific merit of the proposal - i.e. the proposal should be scientifically sound, ethical, and have the potential to contribute to the advancement of public health. The feasibility of the research proposal - i.e. the requesting research team must be scientifically qualified and have the resources to conduct the proposed project. Maintenance of personal integrity - i.e. Sobi will not consider sharing individual data if there is a risk of re-identification of individuals despite a proper anonymisation. Moreover, the patients' informed consent will always be respected. Sobi reserves the right to reject the proposal if the anonymisation process will render unusable data. Publication of results - the applicants should commit to submit their findings to a peer-reviewed scientific journal, alternatively to present the results at a congress (poster or similar), regardless of the research outcome

Data sharing details ↗ · www.sobi.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in May 2026, 14 months.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 14 months is above that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Aug 30, 2024
StartActual
Feb 24, 2025
Primary completionActual
May 21, 2026
CompletionActual
May 21, 2026
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06579144
Collaborators
PSI CRO
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Feb 24, 2025
Primary completion
May 21, 2026
Completion
May 21, 2026
Last update
Jun 25, 2026

Study contacts

Elena Santagostino, MD
study director · Sobi AB

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efanesoctocog alfa

Start the discussion